Pharsight

Drugs that contain Teduglutide Recombinant

1. Gattex Kit patents expiration

GATTEX KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5789379 TAKEDA PHARMS USA Glucagon-like peptide-2 analogs
Apr, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5789379

(Pediatric)

TAKEDA PHARMS USA Glucagon-like peptide-2 analogs
Oct, 2020

(3 years ago)

US7056886 TAKEDA PHARMS USA GLP-2 formulations
Sep, 2022

(1 year, 7 months ago)

US7056886

(Pediatric)

TAKEDA PHARMS USA GLP-2 formulations
Mar, 2023

(1 year, 1 month ago)

US9539310 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US7847061 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9993528 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9572867 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9974835 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9592273 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9592274 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9555079 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9987334 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9981016 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9981014 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9974837 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9968658 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9987335 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9545435 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9968655 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9060992 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9545434 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9968656 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 6 months from now)

US9545435

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9060992

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9592274

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9592273

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9572867

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9987335

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9993528

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9545434

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9555079

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US7847061

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9981016

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9968658

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9974835

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9974837

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9968656

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9968655

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9987334

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9981014

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

US9539310

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-240) May 16, 2026
Orphan Drug Exclusivity(ODE-37) Dec 21, 2019
Pediatric Exclusivity(PED) Jun 21, 2020
Orphan Drug Exclusivity(ODE) Dec 21, 2019
New Chemical Entity Exclusivity(NCE) Dec 21, 2017

NCE-1 date: 22 June, 2019

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

GATTEX KIT family patents

Family Patents